Nauck, M. A., & Quast, D. R. (2021). Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne).
Styl ChicagoNauck, Michael A., a Daniel R. Quast. "Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6." Front Endocrinol (Lausanne) 2021.
Citace podle MLANauck, Michael A., a Daniel R. Quast. "Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6." Front Endocrinol (Lausanne) 2021.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..